1
|
Pan Y, Jiang Y, Cui Y, Zhu J, Yu Y. Truncated Lactoferricin peptide controls cervical cancer cell proliferation via lncRNA-NKILA/NF-κB feedback loop. Protein Pept Lett 2021; 29:268-280. [PMID: 34872471 DOI: 10.2174/0929866528666211206144110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/25/2021] [Accepted: 10/05/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Lactoferricin peptide (LP) has been reported to control cancer cell proliferation. NF-κB interacting lncRNA (NKILA) is a tumor suppressor in several cancers. OBJECTIVE We aimed to explore the potential function of the truncated LP (TLP) in the prevention of cervical cancer cell proliferation. METHODS Bioinformatics analysis via PPA-Pred2 showed that 18-aa N-terminus of truncated lactoferricin peptide (TLP18, FKCRRWQWRMKKLGAPSI) shows higher affinity with nuclear factor kappaB (NF-κB) than LP. The effects of LP and TLP18 on cervical cancer cells SiHa and HeLa and the related mechanisms were explored by investigating NF-κB and lncRNA-NKILA. RESULTS TLP18 shows an inhibitory rate up to 0.4-fold higher than LP on the growth of cervical cancer cells (P<0.05). NKILA siRNA promoted cell growth whether LP or TLP18 treatment (P<0.05). TLP18 treatment increases the level of lncRNA-NKILA and reduces the level of NF-κB up to 0.2-fold and 0.6-fold higher than LP (P<0.05), respectively. NKILA siRNA increased the levels of NF-κB, cleaved caspase-3, and BAX (P<0.05). TLP18 increased apoptotic cell rate up to 0.2-fold higher than LP, while NKILA siRNA inhibited cell apoptosis cell growth even LP or TLP18 treatment. CONCLUSION Truncated Lactoferricin peptide controls cervical cancer cell proliferation via lncRNA-NKILA/NF-κB feedback loop.
Collapse
Affiliation(s)
- Yuan Pan
- Reproductive medical center, The First Hospital of Jilin University, Changchun 130021. China
| | - Yuting Jiang
- Reproductive medical center, The First Hospital of Jilin University, Changchun 130021. China
| | - Yingli Cui
- Department of gynecology oncology, The First Hospital of Jilin University, Changchun 130021. China
| | - Jihong Zhu
- Reproductive medical center, The First Hospital of Jilin University, Changchun 130021. China
| | - Yang Yu
- Reproductive medical center, The First Hospital of Jilin University, Changchun 130021. China
| |
Collapse
|
2
|
Chen R, Cheng Q, Owusu-Ansah KG, Song G, Jiang D, Zhou L, Xu X, Wu J, Zheng S. NKILA, a prognostic indicator, inhibits tumor metastasis by suppressing NF-κB/Slug mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Biol Sci 2020; 16:495-503. [PMID: 32015685 PMCID: PMC6990899 DOI: 10.7150/ijbs.39582] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 11/24/2019] [Indexed: 02/07/2023] Open
Abstract
The metastasis of hepatocellular carcinoma (HCC) is one of the major obstacles hindering its therapeutic efficacy, leading to low surgical resection rate, high mortality and poor prognosis. Accumulating evidence has shown that both long noncoding RNA (lncRNA) and NF-κB play vital roles in the regulation of cancer metastasis. However, the clinical significance and biological function of NKILA (NF-κB interacting lncRNA) and its interaction with NF-κB in HCC remain unknown. In this study, we demonstrated that NKILA was down-regulated in HCC tissues and cell lines, and decreased NKILA expression was significantly associated with larger tumor size and positive vascular invasion in HCC patients. NKILA reduction was an independent risk factor of HCC patients' poor prognosis, and the 5-year overall survival (OS) rates of patients with low and high NKILA expression were 15.6% and 60.0%, respectively. Moreover, NKILA inhibits migration and invasion of HCC cells both in vitro and in vivo. Mechanistically, NKILA prevents Slug/epithelial to mesenchymal transition (EMT) pathway via suppressing phosphorylation of IκBα, p65 nuclear translocation and NF-κB activation. In conclusion, these results indicate that NKILA might serve as an effective prognostic biomarker and a promising therapeutic target against HCC metastasis.
Collapse
Affiliation(s)
- Ronggao Chen
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China
| | - Qiyang Cheng
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China
| | - Kwabena Gyabaah Owusu-Ansah
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China
| | - Guangyuan Song
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China
| | - Donghai Jiang
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou 310000, China
| | - Lin Zhou
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou 310000, China
| | - Xiao Xu
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou 310000, China
| | - Jian Wu
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou 310000, China
| | - Shusen Zheng
- Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.,NHFPC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310000, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS.,Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.,Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou 310000, China
| |
Collapse
|
3
|
Bian D, Gao C, Bao K, Song G. The long non-coding RNA NKILA inhibits the invasion-metastasis cascade of malignant melanoma via the regulation of NF-ĸB. Am J Cancer Res 2017; 7:28-40. [PMID: 28123845 PMCID: PMC5250678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 11/29/2016] [Indexed: 06/06/2023] Open
Abstract
The long non-coding RNA (lncRNA) NKILA has been reported to participate in the development of human cancers. The purpose of this study was to explore the potential role of lncRNA-NKILA, which acts through NF-ĸB, in the process of melanoma development. Real-time PCR (qRT-PCR) showed that NKILA was expressed at low levels in human melanoma tissues. The area under the ROC curve of NKILA was 0.875, which indicated that NKILA may be a potential diagnostic biomarker of melanoma. Our results also indicated that NKILA inhibited the progression of cell proliferation, migration, and invasion, and promoted apoptosis of melanoma cells. Furthermore, qRT-PCR showed that NF-κB, which was negatively correlated with NKILA, was highly expressed in human melanoma tissues. Moreover, our results indicated that NKILA inhibited the carcinogenesis of melanoma cells through the inhibition of NF-ĸB in vitro. More importantly, we found that NKILA suppressed the growth of melanoma tumors via NF-ĸB in vivo. In conclusion, NKILA suppressed the development of malignant melanoma via the regulation of NF-ĸB and may be a potential therapeutic target in patients with melanoma.
Collapse
Affiliation(s)
- Donghui Bian
- Department of Burns and Plastic Surgery, The General Hospital of Jinan Military Command25 Shifan Road, Jinan 250031, Shandong, P. R. China
| | - Cong Gao
- Department of Burns and Plastic Surgery, Jinan Central Hospital Affiliated with Shandong University105 Jiefang Road, Jinan 250013, Shandong, P. R. China
| | - Kai Bao
- Department of Burns and Plastic Surgery, Jinan Central Hospital Affiliated with Shandong University105 Jiefang Road, Jinan 250013, Shandong, P. R. China
| | - Guodong Song
- Department of Burns and Plastic Surgery, Jinan Central Hospital Affiliated with Shandong University105 Jiefang Road, Jinan 250013, Shandong, P. R. China
| |
Collapse
|